Up to 70% of non-small cell lung cancer (NSCLC) patients develop central nervous system (CNS) metastases during the course of their disease, especially those with oncogenic drivers treated with a first-generation tyrosine kinase inhibitor (TKI), because of the relatively poor CNS penetration. CNS metastases are associated with a negative impact on quality of life and survival. As, with the introduction of newer generation TKIs, the survival rates are increasing in this particular population, treatment and/ or prevention of CNS metastases becomes even more relevant and the TKI with the best CNS efficacy should be selected. Unfortunately, CNS efficacy data in clinical trials are not fully comparable. Furthermore, oligoprogression to the brain without extracranial progression regularly occurs in the oncogenic driver population and both local therapy and switch of systemic therapy are possible treatment options. However, the best order of systemic and local therapy is still not precisely known. In this narrative review, we will summarize incidence and treatment of CNS metastases in oncogene driven NSCLC, including the optimal treatment of CNS oligometastatic disease (synchronous as well as oligoprogressive).

, , ,
doi.org/10.21037/tlcr-20-459, hdl.handle.net/1765/134376
Translational Lung Cancer Research
Department of Pulmonology

Schoenmaekers, J.J.A.O. (Janna Josephus Anna Oda), Paats, M., Dingemans, A.-M.C. (Anne-Marie Clasina), & Hendriks, L.E.L. (Lizza Elisabeth Lucia). (2020). Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: How to treat and when?. Translational Lung Cancer Research (Vol. 9, pp. 2599–2617). doi:10.21037/tlcr-20-459